Back to UBS Group AG UBS Group AG

NRIXNRIX
Showing 8 of 22 quarters

Position history for UBS Group AGUBS Group AG's holdings in NURIX THERAPEUTICS INC

UBS Group AG holds 917,117 shares of NRIX (NURIX THERAPEUTICS INC), worth $22.2M as of 2026-Q2. The position was decreased (-6.1% shares). NRIX represents 0.0% of UBS Group AG's portfolio.

Current Value

$22.2M

Current Shares

917,117

Total Value Change

+$19.9M

Total Shares Change

+814,251

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Decreased
917,117
-6.1%
$22.2M0.0%$24.26
0
2026-Q1
Increased
976,362
+130.6%
$15.1M0.0%$15.81
45
2025-Q4
Increased
423,425
+16.8%
$8M0.0%$19.02
32
2025-Q3
Decreased
362,546
-77.2%
$3.3M0.0%$9.28
0
2025-Q2
Increased
1.6M
+136.1%
$18.1M0.0%$11.64
46
2025-Q1
Increased
673,147
+796.2%
$8M0.0%$12.15
44
2024-Q4
Decreased
75,113
-27.0%
$1.4M0.0%$18.64
0
2024-Q3
Decreased
102,866
-13.2%
$2.3M0.0%$23.05
0

Other major holders of NRIX: BlackRock, Inc., FMR LLC, BlackRock Finance, Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used